A detailed history of Morgan Stanley transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,326,134 shares of CCCC stock, worth $9.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,326,134
Previous 1,137,938 104.42%
Holding current value
$9.19 Million
Previous $5.26 Million 152.2%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.43 - $7.38 $5.26 Million - $8.77 Million
1,188,196 Added 104.42%
2,326,134 $13.3 Million
Q2 2024

Oct 17, 2024

BUY
$4.05 - $8.1 $2.53 Million - $5.05 Million
623,755 Added 121.31%
1,137,938 $5.26 Million
Q2 2024

Aug 14, 2024

BUY
$4.05 - $8.1 $2.53 Million - $5.05 Million
623,755 Added 121.31%
1,137,938 $5.26 Million
Q1 2024

Oct 17, 2024

SELL
$5.3 - $11.0 $3.31 Million - $6.86 Million
-623,755 Reduced 54.81%
514,183 $4.2 Million
Q1 2024

Aug 16, 2024

BUY
$5.3 - $11.0 $1.64 Million - $3.4 Million
308,842 Added 150.4%
514,183 $4.2 Million
Q1 2024

May 15, 2024

BUY
$5.3 - $11.0 $1.64 Million - $3.4 Million
308,842 Added 150.4%
514,183 $4.2 Million
Q4 2023

Aug 16, 2024

SELL
$1.18 - $6.03 $1.1 Million - $5.62 Million
-932,597 Reduced 81.95%
205,341 $1.16 Million
Q4 2023

Feb 13, 2024

SELL
$1.18 - $6.03 $127,128 - $649,648
-107,736 Reduced 34.41%
205,341 $1.16 Million
Q3 2023

Nov 15, 2023

BUY
$1.81 - $3.89 $130,388 - $280,227
72,038 Added 29.89%
313,077 $582,000
Q2 2023

Aug 14, 2023

SELL
$2.75 - $3.77 $146,022 - $200,183
-53,099 Reduced 18.05%
241,039 $662,000
Q1 2023

May 15, 2023

SELL
$3.1 - $9.02 $263,689 - $767,250
-85,061 Reduced 22.43%
294,138 $923,000
Q4 2022

Feb 14, 2023

BUY
$5.42 - $10.24 $188,681 - $356,474
34,812 Added 10.11%
379,199 $2.24 Million
Q3 2022

Nov 14, 2022

SELL
$8.03 - $12.77 $891,884 - $1.42 Million
-111,069 Reduced 24.39%
344,387 $3.02 Million
Q2 2022

Oct 27, 2022

SELL
$5.06 - $26.46 $1.02 Million - $5.35 Million
-202,116 Reduced 30.74%
455,456 $3.43 Million
Q2 2022

Aug 15, 2022

SELL
$5.06 - $26.46 $1.02 Million - $5.35 Million
-202,116 Reduced 30.74%
455,456 $3.43 Million
Q1 2022

Oct 27, 2022

BUY
$19.99 - $33.23 $4.04 Million - $6.72 Million
202,116 Added 44.38%
657,572 $16 Million
Q1 2022

May 13, 2022

SELL
$19.99 - $33.23 $5.22 Million - $8.67 Million
-260,898 Reduced 28.41%
657,572 $16 Million
Q4 2021

Feb 14, 2022

BUY
$29.39 - $46.86 $18.5 Million - $29.4 Million
628,374 Added 216.61%
918,470 $29.6 Million
Q3 2021

Nov 15, 2021

BUY
$35.91 - $50.5 $10.4 Million - $14.6 Million
290,096 New
290,096 $13 Million

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $193M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.